Drugs / MV-014-212
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04798001 | Apr 2021 → Oct 2022 | COVID-19 | Meissa Vaccines, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MV-014-212 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04798001 ↗ |
| Modality | Vaccine | “live attenuated vaccine against respiratory syncytial virus (RSV)” NCT04798001 ↗ |
| Route | Intranasal | “MV-014-212 is administered as drops or a spray in the nose.” NCT04798001 ↗ |